OuiO will receive software security with this partnership for its Si One, for specialty drugs, and Si Pen, for diabetes patients. MedCrypt’s software will be able to sync with the drug delivery sensors to automatically send real-time dosing data. MedCrypt’s software will help monitor device usage for suspicious behavior. Encrypted and properly signed data will also be able to be communicated through ConnectedRx, QuiO’s cloud platform.
“It’s critical that our bi-directional communication channel remains secure at all times, from both a privacy and safety standpoint,” said QuiO co-founder and CEO Alexander Dahmani. “We’re proud to be working with MedCrypt because their technology has been successfully used to secure some of the highest-risk medical devices in the market and we want every available defense in today’s evolving cybersecurity landscape.”
The FDA recently overhauled the guidelines for how medical device manufacturers develop and vet new products. MedCrypt and QuiO’s partnership comes on the tail end of the new regulations. Health systems have recently experienced security breaches and risked patient protection.
“We are looking forward to making data security a priority in the product development process for QuiO and similarly-staged companies,” said MedCrypt co-founder and CEO Mike Kijewski. “Smartinjector devices have the ability to reduce medical costs for patients and give them a portable therapy device they can take with them anywhere. As the bi-directional flow of data intensifies, we want to ensure accuracy and safety at every step.”
MedCrypt’s software is able to use machine-learning to detect any cybersecurity threats before they attack as QuiO’s products face a rise in product demand, after having being recognized by Accenture at the Startup Health Festival as being a better option for patients administering injectable therapies.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]